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Introduction
Atrial septal defect (ASD) is a common form of congenital 
heart disease accounting for approximately 10% of all 
congenital cardiac defects.1 Surgical closure has been 
for many years, the gold standard treatment for patients 
with ASDs.2,3 In 1976 Mills and King reported the first 
transcatheter closure of secundum ASD4, since then 
transcatheter closure of secundum ASD has evolved over 
the past few decades and is being increasingly used as the 
primary intervention in recent years. Surgical repair has 
been proven to be superior to medical treatment in ostium 
primum and sinus venosus type ASDs, as well as in a 
proportion of secundum type defects which are unsuitable 
for device closure5, with a low operative mortality and high 
long-term survival in middle-aged and elderly patients.6,7
The diagnosis and management of ASD in both pediatric 
and adult populations have benefited greatly from 
major advances over the last few years8 including 3 
dimensional and intracardiac echocardiography, as well 
as percutaneous device closure. Despite these advances, 
ASDs remain “the most under diagnosed congenital heart 
disease in the adult age group”, with age at diagnosis being 
clearly linked to subsequent complications including the 
late development of pulmonary hypertension and atrial 
dysrhythmias.9 
As part of the general evolution of techniques in cardiac 
surgery, emphasis has been placed on shorter incisions 
and other surgical methods proposed as “less” or as 
“minimally” invasive techniques, including minimal 
access, port access, robotics, video-assisted, etc.7,10-
12 Complete closure of ASDs has been achieved less 
frequently with transcatheter techniques than with 
surgery. On the other hand, surgery results in a significant 
morbidity.13,14 However, there are no single regional and 
national reports of comparisons of early results, closure 
rates, mortality, morbidity, and complications between 
patients treated with either transcatheter or surgical 
closure of ASD performed at the same time and in the 
same institution.
The purpose of this study was to compare the safety and 
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Abstract
Introduction: This study compares the effectiveness and cost of trans-catheter verses surgical 
closure of secundum atrial septum defect (ASD). ASD accounts for 10% of congenital cardiac 
defects. Trans-catheter closure of secundum ASD is increasingly used as the primary intervention. 
Surgical repair is advised in a proportion of secundum type defects which are unsuitable for 
device closure.
Methods: We reviewed the clinical course of 176 patients who underwent closure of isolated 
secundum ASD. The patients were assigned to either the device or surgical group depending upon 
the treatment they received. Successful closure was assessed immediately after the procedure. The 
following outcomes were studied: mortality, morbidity, hospital stay, and costs.
Results: Ninety five  patients were in the surgical group and 81 patients were in the group 
undergoing device closure. The median age was 14.0 years (range 1.1-61.0) for surgical group 
and 24.0 years (range 0.5-68.0) for the device group. The mortality in both groups was 0. The 
procedure success rate was 100% for the surgical group and 96.3% for the device group. The 
complication rate was 13.7% for surgical group and 7.4% for the device group. The mean length 
of hospital stay was 5.0 ± 2.7 days for surgical group and 3.0 ± 0.4 days for device group. The 
procedure cost for surgery was found to be 12.3% lower than that of trans-catheter closure.
Conclusion: Successful closure is achieved by both methods. Trans-catheter closure results in 
lower rate of complication and hospital stay but the cost of the procedure tends to be higher 
than surgery.
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efficacy of transcatheter device closure of secundum 
ASD with concurrent surgical repair results in a single 
institution.
Material and methods
Eligibility Criteria
We reviewed charts of 176 patients who were admitted 
for closure of secundum ASD either by surgery or device 
closure between June 2006 to July 2012 and returned 
for early or late follow-up at the Aga Khan University 
Hospital. The inclusion criteria for both groups consisted 
of the presence of an isolated secundum ASD (diameter 
of ≤33 mm for device group; while no limit for surgery 
group), a left to right shunt with Qp/Qs ratio ≥ 1.5:1 or 
patients with small defect but history of paradoxical 
embolism. Excluded from the study were those who had 
other types of ASD (foramen primum or sinus venosus) 
or the presence of an additional cardiac malformation 
[ventricular septal defect (VSD), tetralogy of Fallot, 
pulmonary stenosis etc.)]amenable only by surgical repair.
Additional exclusion criteria for the percutaneous 
closure group were patients with multiple defects 
that were unsuitable by device closure or a defect too 
close to the superior vena cava, atrioventricular valve, 
coronary sinus or pulmonary veins (predictable failure of 
interventional procedure).
Patients who met the inclusion criteria for both groups 
were given an option for opting either procedure. They 
were presented with the complications associated 
with each procedure (intervention with a chance of 
embolization and surgery with a higher rate of morbidity) 
before they made their decision. 
Operative Technique 
Surgery
All surgical procedures were done using cardiopulmonary 
bypass. The chest was opened by via median sternotomy. 
After total cardiopulmonary bypass had been achieved 
either cold blood or crystalloid cardioplegic solution was 
given antegrade through the aortic root. The method used 
to close the defect depended on its size and anatomical 
type. Three patients (3.2%) underwent direct suture 
closure while the rest were closed by autologous pericardial 
patch with Prolene 5-0 suture.
Device Implantation 
The occlusion device used was the Amplatzer Septal 
Occluder. This was because it is the only FDA approved 
available deice in our setting. All percutaneous closure 
was done under general anesthesia. The right femoral vein 
was accessed using a 7–8 Fr short sheath. Heparin was 
administered to achieve an activated clotting time (ACT) 
> 200 seconds at the time of device deployment along with 
1 g cefazolin intravenously. Right heart catheterization was 
performed to ensure the presence of normal pulmonary 
vascular resistance. The defect was sized using a 34 mm 
balloon. The balloon was then inflated with diluted 
contrast until the left to right shunt ceases as observed 
by color flow Doppler TEE (flow occlusion). If the defect 
had adequate rims (>5 mm), we selected a device 0–2 
mm larger than the balloon stretched diameter. However, 
if the superior/anterior rim was deficient (5–7 mm), we 
selected a device 4 mm larger than the balloon stretched 
diameter. Our choice for the device size depended on the 
echocardiographic measurements of the defect (TEE). 
In adults, a device about 4–6 mm larger than the two-
dimensional (2D) size by color Doppler while in children, 
a device no more than 2 mm larger than the 2D size by 
color Doppler was used. Device was deployed with guide 
wire over the left upper pulmonary vein. Position of the 
device was confirmed on fluoroscopy and TEE. Once the 
position of the device was confirmed, it was released. 
Outcomes
Patients who had surgical closure residual intra-
atrial shunting (significant >2 mm) was examined by 
colour Doppler while patients who had device closure 
a transesophageal echocardiogram (TTE) with color 
Doppler was done immediately after the procedure. 
In addition a chest radiograph, an ECG and a physical 
examination was conducted in both groups within 24 h.
Primary Outcome
If death occurred any time after surgery.
Secondary Outcome
Presence of any complications such as residual shunt, 
reintervention, arrhythmias requiring medications, 
pericardial effusion, etc.
Statistical Analysis
Data was analyzed using the SPSS for Windows (version 
19.0) and is expressed as mean, median and minimum 
and maximum ranges where appropriate.
Cost Estimation
Cost per case was calculated based on total hospitalization 
that was reflected on the bill that patient would have 
paid, excluding any subvention. This means that it was 
a true reflection of the actual cost of treatment. The cost 
included hospital room charges, laboratory investigations, 
pharmaceutical charges, clinician and anaesthesia 
charges, facility and treatment charges, cost of surgery 
(including cardiopulmonary bypass) or device and for 
their respective length of stay. In doing so, we were able to 
achieve a meaningful comparison of true costs incurred 
by each patient for either of the methods, which was the 
basis of our comparison. 
Results
A total of 176 patients underwent closure of ASD. Eighty-
one patients for device closure and 95 patients for surgery 
satisfied the inclusion criteria and were included as 
subjects in each arm of study. The median age at operation 
for the device group was comparatively higher, 24.0 years 
(range 0.5-68 years) while of the surgery group was 14.0 
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years (range 1.1 -61 years). A comparison of demographic 
and preoperative variables is illustrated in Table 1.
Comparison of Closure Results
The device group consisted of 81 patients, 32 males (39.5%) 
and 49 females (60.5%).Of the 81 patients, 78 had devices 
successfully deployed (96.3%) across the atrial septum. In 
3 (3.7%) of the patients the device embolized soon after 
implantation and had to be removed surgically. These 
patients will be discussed subsequently. These 3 patients 
have been included in both transcatheter and surgical 
category since they had an immediate successful closure 
but due to embolization were later surgically treated. There 
were 11 candidates who had been initially considered 
suitable for device closure based on transthoracic 
echocardiography. However, device implantation was 
not attempted in these subjects since on trans-esophageal 
echocardiography the ASD was found to have a deficient 
rim (one of either inferior, superior or aortic rim) and were 
thus deferred for surgery (the outcome of these patients is 
included under the surgical data only). The mean size of 
the ASD was 18.9 ± 7.0 mm (range 4 to 33 mm). The mean 
size of the amplatzer device was 23.4 ± 6.7 mm (range 8 to 
34 mm).The mean fluoroscopy time was 14.5 ± 10.3 min 
(range 3.2 to 54 min). 
The surgical group consisted of 95 patients, 50 males 
(52.6%) and 45 females (47.4%). The size of the defect 
ranged from 7 mm to 63 mm, mean 25.2 ± 10.0 mm. The 
mean cardiopulmonary bypass time was 58.7 ± 23.4 min 
and the aortic cross-clamp time was 32.1 ± 15.3 min. The 
mean minimum temperature reached was found to be 
35.5 oC. After each surgery, a postoperative on table echo 
was done to check for the presence of any hemodynamic 
abnormality or for any residual patch defect (significant 
>2 mm). After the procedure inotropic support was 
provided in 50 (52.6%) cases and consisted of either one 
of epinephrine, dopamine, milrinone, dobutamine or a 
combination of epinephrine and milrinone.
All but one patient in the surgical group had a successful 
closure immediately after the procedure. 
A comparison of operative and postoperative outcomes 
Table 1. Comparison of demographic and baseline clinical data 
between surgical and device closure group
Mean ± SD
Surgical Patients 
(n=95)
Device Patients 
(n=81)
Height (cm) 130.9 ± 37.3 141.8 ± 26.5
Weight (kg) 40.0 ± 29.1 44.0 ± 21.6
Age (years) 18.8 ± 16.7 23.3 ± 16.4
Patients with family 
history of ASD
14 3
Pulmonary Hypertension 
(on admission)
14 7
Size of ASD (mm) 24.7 ± 9.9 18.9 ± 7.0
ASD: atrial septum defect
Table 2. Comparison of operative and postoperative outcomes between surgical and device closure group
Mean ± SD
Surgical Patients (n=95) Device Patients (n=81)
Duration of Surgery/Procedure (min) 168.3 ± 38.1 64.2 ± 29.0
CPB Time/Fluoroscopy Time (min) 58.7 ± 23.4 14.5 ± 10.3
Aortic Cross-Clamp Time (min) 32.1 ± 15.3 -
Mean Minimum Temperature (oC) 35.5 ± 1.8 -
Length of CICU stay (days) 1.5 ± 1.1      -
Length of hospital stay (days) 5.0 ± 2.7 3.0 ± 0.4
Residual ASDs (≥2 mm) 0 0
On table deferred for surgery 0 11
Total procedure success (%) 100 96.3
Mean total cost (USD $) 2460.90 ± 443.57 2764.61 ± 528.07
ASD: atrial septum defect; CPB: cardiopulmonary bypass time
between the two groups is demonstrated in Table 2.
Comparison of ICU, Hospital Stay and Procedure Cost
In the device group all patients were shifted immediately 
after percutaneous closure from the cardiac catheterization 
laboratory to the wards. In contrast all surgical patients 
were required to be in the intensive care unit for at least 
one day.
The mean length of inpatient stay for the surgical group 
was 5.0 ± 2.7 days. This was longer than the patients of 
device group 3.0 ± 0.4 days.
The mean cost per successful closure procedure was 
around USD $300 higher for the device. Although the cost 
of radiology and laboratory investigations was higher in 
the surgical group the high cost of the Amplatzer device 
(currently USD $2500) weighted much heavier on the 
overall total charges despite patients in this group had a 
shorter hospital stay.
Comparison of Complications
There were complications observed in both surgical and 
device closure patients. Table 3 summarizes the major 
complications encountered between the two groups.
In the surgery group there were two patients of each 
pleural effusion and pneumothorax. These were treated 
via mechanical drainage and developed no further 
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complication. There was an immediate early surgical 
wound complication in one patient requiring sternal 
wire removal and antibiotic treatment. There was one 
patient which required a reopening, due to misdirection 
of the IVC to the left atrium resulting in post-operative 
desaturation. The patient was taken back to surgery and 
the ASD was closed with IVC draining into the right 
atrium. There were 3 readmissions within 30 days which 
were due to superficial wound infection. The mean time 
for follow-up in the surgical group was 6.8±9.6 months. 
Of the 95 patients only 8 (8.4%) were in NYHA II on 
follow-up and the rest were in NYHA I.
In comparison, patients in device group had a much 
lower rate of complication. Device embolization requiring 
surgical retrieval was the most major complication 
and occurred in 3 patients, shortly after the procedure. 
Cardiac arrhythmia was a common minor complication 
of both groups occurring in 3 patients in device group and 
4 patients in the surgery group. These were brief episodes 
and were resolved by the use of medication. There were 
no cases of vascular complication (groin hematoma) in 
patients treated by cardiac intervention. There was one 
patient who was readmitted due to non-cardiac reasons. 
There were no deaths in either the device or surgical group 
and all patients were discharged in stable conditions from 
the hospital.
Of the 3 devices that were dislodged, one of them was 
a 16 year old girl who developed premature ventricular 
contractions shortly after the procedure. Echocardiogram 
and fluoroscopy revealed the device to be in the right 
ventricle near the tricuspid valve requiring immediate 
surgical retrieval. The second was a 53-year-old female. 
Her pre-discharge echo showed an ASD and fluoroscopy 
Table 3. Comparison of major complications between surgical 
and device closure group 
Surgical 
Patients (n=95)
Device Patients 
(n=81)
Morbidity
Complications (%) 
[on patient-basis]
13.7 7.4
Wound Infections/Groin 
Hematoma 4 0
Pneumonia 1 0
Pericardial Effusion 
(requiring tube 
thoracostomy)
0 0
Pleural Effusion (requiring 
tube thoracostomy)
2 0
Pneumothorax (requiring 
tube thoracostomy)
2 0
Reopening 1 0
Device Embolization 0 3
Device Endocarditis - 0
Arrhythmias (requiring 
medication)
4 3
Readmission within 30 
days)
3 1
revealed the device in the left ventricle. The last case 
was a 16-year-old boy who experienced post-operative 
palpitations. Echocardiogram revealed the device to be 
dislodged in right ventricular outflow tract. All these 
patients were immediately operated surgically. The 
defect was closed using an autologous pericardial patch 
and postoperative echo showed no residual ASD. All of 
them made a smooth postoperative recovery and were 
discharged in stable conditions. On follow-up (2 years, 2 
years and 3.5 months) they were asymptomatic and there 
was no residual ASD demonstrated by echocardiography.
The mean time for follow-up for this group was 10.8 ± 
15.9 months. Out of the 81 patients only 5 (6.2%) were in 
NYHA II while the rest were in NYHA I.
Discussion
ASDs account for 10% of all cardiac malformations in 
childhood.1 If left uncorrected, they may lead to premature 
death from congestive cardiac failure.15 Patients with ASD 
and left to right shunts are at increased risk of developing 
pulmonary arterial hypertension.16 As seen in our data 21 
patients (14 in surgical and 7 in device patients), both of 
pediatric and adult age group had developed pulmonary 
hypertension at the time of presentation. These were 
echocardiographic findings and the outcome of these 
patients improved after treatment.
ASD has been surgically repaired for almost 60 years.17 
However in recent years the transcatheter approach 
to occlude secundum ASD has gained considerable 
popularity. The main advantages of device include: the 
self-centering mechanism, leading to better complete 
closure rates; delivery through relatively small introducing 
sheaths; and simple placement technique and retrievability 
before release. In addition, there are fewer complications, 
avoidance of sternotomy and cardiopulmonary bypass, 
shorter hospital stay, reduced need for blood products and 
less patient discomfort.
This retrospective study describes the advantages and 
complications of each technique. Regardless of the 
method the mortality in both groups was found to be 
zero. However, one of the main finding of our study was 
that the morbidity was higher in surgical group compared 
to the device group. This finding is in accordance with 
other studies.18,19 Although age was not a considered a 
criterion for selection for either procedure, patients in 
the surgical group were relatively much younger and had 
comparatively larger size of defects which could have 
attributed to the complications.
Despite the fact that device closure tends to have fewer 
complications, embolization is a potentially feared one 
which requires immediate surgical intervention for 
retrieval and correction of defect.20 In our institution this 
complication cannot be attributed by our learning curve 
since it occurred late in the course, after implantation of 
more than 50 devices.
The 11 patients that were initially assessed to be suitable 
for device closure on transthoracic echocardiography 
but in the cardiac catheterization lab, on transesophageal 
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echocardiography they were found to have a deficient rim. 
One may question as why we did not do a TEE earlier. 
The reason is being that a TEE is much more expensive 
than TTE and requires the patient to undergo general 
anesthesia. This is a significant financial concern in a 
third world country like Pakistan and hence in our initial 
evaluation, TTE is used as the primary diagnostic tool.
In our study, on follow-up in the device group there were 
no patients who developed device endocarditis which has 
been described as a late complication of this procedure.21
Our analysis revealed that mean surgical closure of ASD 
was USD $ 2460.90 ± 443.57 while of the device group was 
$ 2764.61 ± 528.07 (these costs are inclusive of all expenses: 
cost of device/cardiopulmonary bypass, laboratory, 
pharmaceutical and radiology charges, operating room 
costs etc.) revealing surgery to be 12.3% cheaper. This is 
in correlation with another study by Quek et al24 where 
the mean cost per successful procedure was considerably 
higher for the device group. The difference is largely due 
to the high cost of the device. Other devices might be 
cheaper and may lead to a lower cost of the transcatheter 
procedure but only the Amplatzer was used in our setting.
Nevertheless, there is less utilization of beds and ICU 
facilities which reduces load on hospital resources and 
ancillary staff. 
The monetary difference is significantly important in 
a low-income country like Pakistan where health care 
resources are limited and funds must be allocated in a way 
which allows more number of patients to be effectively 
treated.
Clinical Implication
In our study device closure of ASD seems comparable to 
surgery when the anatomy of the ASD is suitable. Device 
closure technique requires a shorter hospital stay implying 
early resumption of school or work. Surgical closure is of 
course possible for all sizes and anatomical variants of 
ASDs. Open heart surgery has its inherent risk associated 
but the incidence of major complications (device failure 
and embolization) are the same in the two groups.
Limitations
The study had some limitations. When both techniques 
were available, patients treated surgically were those with 
multiple or more complex defects. This could impact on 
the occurrence of complications.
The sample size of the study population was small and this 
was a single-center study, so the results are limited to our 
own experience.
Conclusion
We conclude that in experienced hands, transcatheter ASD 
closure provides comparable results to surgery though 
with a shorter hospital stay. However, device closure of 
ASD should only be done in centers where an immediate 
surgical backup is available. This is the first study of its 
kind evaluating outcomes and costs from Pakistan. 
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